RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Schwabe Kaskad-A

Product
Developers: Shvabe, Bauman Moscow State Technical University of MSTU
Date of the premiere of the system: August, 2016
Branches: Pharmaceutics, medicine, health care

2016: Announcement of the device

At the beginning of August, 2016 the Schwabe holding announced the device for recovery of the hurt soft fabrics and joints and also the broken bones. Innovation under the name "Kaskad-A" as developers report, is unique and should be in demand in all fields of clinical medicine.

The electromagnetic device is created by specialists of "Schwabe" in cooperation with scientific research institute of biomedical equipment of MSTU of Bauman. The device having the stimulating impact on metabolic processes in an organism allows to treat diseases and injuries of soft fabrics and joints. Besides, it promotes the accelerated accretion of bone tissues at changes.

According to the deputy director of Schwabe Dmitry Zhidkov, a product turns on the operation modes adapted for each specific disease.

Russia created the device healing injuries and fractures
File:Aquote1.png
Depending on a clinical task the doctor can set as the "arterial mode" promoting inflow of blood on a certain part of the body, and the "venous mode" intended for removal of hypostasis. The similar multifunctionality considerably expands a device scope — Zhidkov noted.
File:Aquote2.png

The beginning of serial production of a new product is planned on the first half of 2017. The device price at the time of the announcement was not set.

Meanwhile, in July, 2016 the Schwabe holding announced readiness for mass release of a complex for treatment of oncological diseases which is capable to destroy tumors with a diameter up to 4 cm without serious consequences. It is about the low-invasive procedure which does not leave postoperative seams and provides faster recovery of the patient. The holding considers that the new medical device will become the reliable assistant to the oncologist, and note active interest in a complex from the different oncological centers.[1]

Notes